Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dietlein

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
British Journal of Haematology|August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study GroupPaul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaMalik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
Leukemia|October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphomaMichael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 19, 2026
Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell TherapyConrad-Amadeus Voltin, Sarah Flossdorf, Lars Kurch, et al.
The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
British Journal of Haematology|August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study GroupPaul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaMalik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
Leukemia|October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphomaMichael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 19, 2026
Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell TherapyConrad-Amadeus Voltin, Sarah Flossdorf, Lars Kurch, et al.
The Lancet. Haematology|May 28, 2021
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trialStefanie Kreissl, Helen Goergen, Ina Buehnen, et al.
The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.
Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.
Pageof 15